Remicade on PBS for severe colitis

pbsOn 1 April 2014, Remicade® (infliximab) was made available on the Pharmaceutical Benefits Scheme (PBS) in limited circumstances for patients with acute severe ulcerative colitis.

The PBS listing of the biologic medicine provides Australians who are experiencing a sudden severe flare-up of ulcerative colitis (otherwise known as acute severe ulcerative colitis) with a new medical treatment option, when previously an emergency surgery removing their lower bowel constituted the main alternative.

CCA CEO Francesca Manglaviti said: “Many of the people diagnosed with acute severe ulcerative colitis are young. Surgery at this early stage in their lives can have far-reaching consequences impacting both their physical condition and their psychological health.”

“The introduction of Remicade®to the PBS is a welcome development, but there is still work to be done. Until we discover a cure, we need to ensure that all people living with IBD receive the best possible care and treatment. This will allow them to manage their disease, empowering them to choose the life they want to live rather than having a disease dictate what they can and can’t do.”